Published in
Elsevier, Annals of Oncology, 3(25), p. 657-662, 2014
Links
- ORCID
- Elsevier
- ORCID
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [www.ncbi.nlm.nih.gov] | PDF
- [europepmc.org] | PDF
Tools
Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer
Journal article published in 2014 by
R. Leibowitz-Amit,
A. J. Templeton,
A. Omlin,
C. Pezaro,
E. G. Atenafu 
,
D. Keizman,
F. Vera-Badillo,
J.-A. Seah,
G. Attard,
J. J. Knox,
S. S. Sridhar,
I. F. Tannock,
J. S. de Bono ,
A. M. Joshua
,
D. Keizman,
F. Vera-Badillo,
J.-A. Seah,
G. Attard,
J. J. Knox,
S. S. Sridhar,
I. F. Tannock,
J. S. de Bono ,
A. M. Joshua
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Abiraterone is a new hormonal drug for metastatic castration resistant prostate cancer. In a retrospective analysis, neutrophil/lymphocyte ratio (NLR) ≤ 5 and restricted metastatic spread to either bones or lymph nodes were associated with PSA response to abiraterone. These two variables were combined to a score that was associated with PSA response and OS, in both a training and a validation cohort.